AVI BioPharma (AVII) Says Eteplirsen Met Primary Endpoint in DMD Following Phase IIb Trial
Go back to AVI BioPharma (AVII) Says Eteplirsen Met Primary Endpoint in DMD Following Phase IIb Trial| AVI BioPharma, Inc. (NASDAQ: AVII) | Delayed: 0.66 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.66 | 52 Week High | $1.68 | |||
| Open | $71.89 | 52 Week Low | $0.43 | |||
| Day High | $0.66 | P/E | N/A | |||
| Day Low | $0.66 | EPS | $-0.16 | |||
| Volume | 38,332 | |||||
